<DOC>
	<DOCNO>NCT00351832</DOCNO>
	<brief_summary>This study conduct United States . Vildagliptin oral antidiabetic agent . This 12-week clinical study evaluate effect vildagliptin 50mg qd , 50mg bid 100mg qd compare placebo patient type 2 diabetes .</brief_summary>
	<brief_title>A Study To Compare Effect Vildagliptin Compared Placebo Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis type 2 diabetes Patients place dietary therapy/exercise therapy without achievement glycemic control Outpatients Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes Significant cardiovascular disease Significant diabetic complication Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Hemoglobin A1c</keyword>
</DOC>